Eli Lilly And Company ((LLY)), Loxo Oncology Inc ((LOXO)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Eli Lilly and Loxo Oncology are conducting a Phase 3 study titled ‘A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)’. The study aims to evaluate the efficacy and safety of a combination treatment involving Pirtobrutinib, Venetoclax, and Rituximab compared to Venetoclax and Rituximab alone in patients with previously treated CLL/SLL.
The study tests two interventions: Arm A involves Pirtobrutinib, Venetoclax, and Rituximab, while Arm B involves Venetoclax and Rituximab. Pirtobrutinib and Venetoclax are oral drugs, and Rituximab is administered intravenously.
This interventional study follows a randomized, parallel assignment model with no masking, focusing on treatment as its primary purpose. Participants are randomly assigned to one of the two treatment arms.
The study began on September 20, 2021, with an estimated completion date in 2025. The last update was submitted on July 1, 2025, indicating ongoing progress.
The outcome of this study could significantly influence Eli Lilly and Loxo Oncology’s stock performance, given the potential for a new treatment option in the competitive CLL/SLL market. Success in this trial could enhance investor confidence and position the companies favorably against competitors.
The study is ongoing, with further details accessible on the ClinicalTrials portal.